share_log

Walgreens Boots Alliance | 8-K: Current report

Walgreens Boots Alliance | 8-K: Current report

沃尔格林-联合博姿 | 8-K：重大事件
美股sec公告 ·  05/01 17:03
Moomoo AI 已提取核心信息
Walgreens Boots Alliance, Inc. (Walgreens) has reached a settlement in a shareholder derivative suit involving allegations of inadequate oversight of opioid-related matters. The suit, initially filed in Ohio and later refiled in Illinois, claimed that certain officers and directors breached fiduciary duties by failing to ensure compliance with the Controlled Substances Act, exposing the company to liability. The settlement, mediated by Hon. Layn R. Phillips (Ret.), includes a $36 million payment from directors and officers insurance carriers and the implementation of corporate governance reforms for at least five years. The reforms include the creation of a Compliance, Safety, and Quality Committee, the appointment of two new independent directors, and the establishment of a U.S. Retail Pharmacy Governance, Risk, and Compliance Committee, among other changes. The settlement is subject to court approval, with a hearing scheduled to determine its fairness, reasonableness, and adequacy, as well as to address any objections from shareholders.
Walgreens Boots Alliance, Inc. (Walgreens) has reached a settlement in a shareholder derivative suit involving allegations of inadequate oversight of opioid-related matters. The suit, initially filed in Ohio and later refiled in Illinois, claimed that certain officers and directors breached fiduciary duties by failing to ensure compliance with the Controlled Substances Act, exposing the company to liability. The settlement, mediated by Hon. Layn R. Phillips (Ret.), includes a $36 million payment from directors and officers insurance carriers and the implementation of corporate governance reforms for at least five years. The reforms include the creation of a Compliance, Safety, and Quality Committee, the appointment of two new independent directors, and the establishment of a U.S. Retail Pharmacy Governance, Risk, and Compliance Committee, among other changes. The settlement is subject to court approval, with a hearing scheduled to determine its fairness, reasonableness, and adequacy, as well as to address any objections from shareholders.
Walgreens Boots Alliance, Inc.（Walgreens）已就一项股东衍生诉讼达成和解，该诉讼涉及对阿片类药物相关事项监督不力的指控。该诉讼最初在俄亥俄州提起，后来在伊利诺伊州重新提起，声称某些高管和董事未能确保遵守《管制物质法》，从而违反了信托义务，使公司面临责任。该和解协议由莱恩·菲利普斯阁下（退休）调解，包括董事和高级管理人员保险公司支付的3,600万美元款项，以及实施至少五年的公司治理改革。这些改革包括成立合规、安全和质量委员会，任命两名新的独立董事，以及成立美国零售药房治理、风险和合规委员会等。该和解尚待法院批准，并计划举行听证会，以确定其公平性、合理性和充分性，并解决股东的任何异议。
Walgreens Boots Alliance, Inc.（Walgreens）已就一项股东衍生诉讼达成和解，该诉讼涉及对阿片类药物相关事项监督不力的指控。该诉讼最初在俄亥俄州提起，后来在伊利诺伊州重新提起，声称某些高管和董事未能确保遵守《管制物质法》，从而违反了信托义务，使公司面临责任。该和解协议由莱恩·菲利普斯阁下（退休）调解，包括董事和高级管理人员保险公司支付的3,600万美元款项，以及实施至少五年的公司治理改革。这些改革包括成立合规、安全和质量委员会，任命两名新的独立董事，以及成立美国零售药房治理、风险和合规委员会等。该和解尚待法院批准，并计划举行听证会，以确定其公平性、合理性和充分性，并解决股东的任何异议。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息